

# **Development of PCOD questionnaire original research**

### <sup>1</sup> Revathi Srinivasan

Associate Professor, Dr BR Ambedkar college of physiotherapy Kadugondahali, Tannery Road, Bengaluru, Karnataka, 560045. <sup>2</sup>Bhoomika B S, Riya Thomas Student, Dr BR Ambedkar college of physiotherapy Bengaluru, Karnataka, 560045. <sup>3</sup>A.K. Vijaykrishna Kumar Principal and Professor, Dr BR Ambedkar college of physiotherapy Bengaluru, Karnataka, 560045.

Received: 10<sup>th</sup> April 24 Revised: 5<sup>th</sup> June 24 Accepted: 1<sup>st</sup> July 24

# ABSTRACT

**Background**: Polycystic ovarian disease (PCOD) is of clinical and public health importance, as it is very common, affecting up to one in five women of reproductive age, with 70% undiagnosed. ASRM/ESHRE criteria include ultrasound for diagnosis since 2003. Given limited diagnostic tools, a new PCOD scale or questionnaire is being developed to assess symptoms, aiming to enhance patient evaluation.

**Objectives:** The purpose of this study is to develop a new PCOD scale or questionnaire to assess patients, focusing on the symptoms of PCOD.

**Methodology:** 277 individuals received a Google Forms questionnaire, categorized into PCOD diagnosis and exclusion criteria, with 174 and 103 respondents respectively. Bio statistical analysis evaluated questionnaire reliability, content validity, sensitivity, and specificity.

**Materials and methods**: A Likert scale questionnaire, reviewed at Dr. B.R. Ambedkar Medical College, was sent to 277 women aged 18-45 via WhatsApp and email from August 1 to September 15, 2023. Bio statistical analysis on September 16, 2023, evaluated reliability, validity, sensitivity, and specificity, with 174 PCOD-diagnosed respondents

**Result:** The study confirmed the self-made PCOD diagnosis questionnaire's reliability (Cronbach's alpha: 0.890) and validity (96%). It showed high internal consistency and construct validity. Content validity met the satisfactory level at 96%. Sensitivity identified PCOD-positive cases, while specificity accurately detected PCOD-negative cases at 60.2%.

**Conclusion:** The study found that women using the self-made questionnaire for early PCOD diagnosis, can score up Points, with surpassing 15.5 indicating a high likelihood of PCOD positivity.

Keywords: Early diagnosis, PCOD, Questionnaire

#### **INTRODUCTION**

In growing and evolved countries, the most common endocrine disorder in women of childbearing age is polycystic ovarian disease, affecting 5-10% of the population <sup>(2)</sup>. The disorder is associated with a variety of clinical features, including reproductive disorders (infertility, hyperandrogenism, hirsutism), metabolic disorders (insulin resistance, glucose intolerance, type 2 diabetes), risk of cardiovascular events, and affects psychological



#### e-ISSN 2583 4304

Vol: 3, Issue: 3

features <sup>(1)</sup>. The exact pathophysiology of PCOD is complex and largely unknown. may PCOD be misdiagnosed or underdiagnosed due to inconsistent diagnostic criteria, ignorance of medical professionals, and variability in her PCOD phenotype <sup>(3)</sup>. Additionally, many women are unaware that they have PCOD and may proper evaluation not receive and treatment, putting them at risk for PCOD. (1)

The prevalence of PCOD has traditionally been estimated at 4-8% in studies in Greece, Spain, Australia, Asia, and the United States <sup>(1)</sup>. The prevalence of PCOD has increased with the use of different diagnostic criteria and was recently demonstrated to be 18% in the first community-based prevalence study based on current Rotterdam diagnostic criteria<sup>(1)</sup>. The main diagnostic steps to confirm PCOD are an ultrasound scan and a series of blood tests based on hormone levels <sup>(3)</sup>. In addition, key clinical feature-based questionnaires and scales to identify PCOD would be useful in epidemiologic studies of female reproductive health <sup>(3)</sup>. This is because such questionnaires can be distributed to large groups of women without the need for expensive hospital visits or diagnostic blood tests. The purpose of this study is to develop a scale or questionnaire to assess PCOD based on the first symptoms to assist women at risk of PCOD and increase public awareness of PCOD.

#### **OBJECTIVE OF THE STUDY**

The purpose of this study is to develop a new PCOD scale or questionnaire to assess patients, focusing on the symptoms of PCOD.

# METHODOLOGY

Study design: survey study Sampling method: purposive sample Sample size: 277 Sample setting: online platform, via google forms.

## **MATERIALS AND METHOD**

This self-designed questionnaire, employing a Likert scale, comprises five demographic questions, four preliminary questions, and 14 main questions related to PCOD symptoms. The 14 questions were formulated in reference to the Rotterdam criteria and existing **PCOD-related** questionnaires, covering topics such as weight irregular periods. gain. dermatological conditions, psychological symptoms, daily activities, and infertility, among others <sup>(1)</sup>. The questionnaire underwent a review process by experts in the field of obstetrics and gynaecology at Hospital Medical College and in Bengaluru, India on 19<sup>th</sup> July 2023. Suggestions provided by the experts were incorporated, and the final questionnaire was transformed into a Google Forms format. It was then distributed via WhatsApp and email to 277 women aged between 18-45 years, from 1<sup>st</sup> august 2023 to 15<sup>th</sup> September 2023 ensuring the consent from all participants. Out of this group, 174 women were diagnosed with PCOD, while 103 women were not diagnosed with PCOD. The collected data from the questionnaire were shared with a biostatistician on 16<sup>th</sup> September 2023 for statistical analysis to assess the reliability, validity. construct validity, content sensitivity and specificity of the selfdesigned questionnaire.



e-ISSN 2583 4304

Vol: 3, Issue: 3

July 2024; 3(3s):

# **INCLUSION CRITERIA:**

Age between 18 to 44 years Women diagnosed with PCOD, not diagnosed with PCOD

## STATISTICAL ANALYSIS

Regarding the questionnaire instrument, Likert scale was employed. The rating required respondents to determine the level of a variable. The baseline data compares individuals with and without Polycystic OverIan disease (PCOD) across key variables. On average, those with PCOD are younger (mean age 24.017 years) compared to those without PCOD (mean age 24.932 years). PCOD individuals tend to be shorter (average height 146.226 cm)

#### **EXCLUSION CRITERIA:**

Age above 45 Post menopause

with greater variability, while non-PCOD individuals are taller (mean height 153.177 cm) with less variability. In terms of weight, PCOD individuals weigh more on average (mean weight 59.220 kg) with higher variability, whereas non-PCOD individuals weigh less on average (mean weight 54.068 kg) with lower variability. Age at menarche is also lower on average for PCOD individuals (mean age 13.063 years) compared to non-PCOD individuals (mean age 13.796 years).

|                |            |     |         | Std.      |
|----------------|------------|-----|---------|-----------|
| Base line data |            | N   | Mean    | Deviation |
| AGE            | PCOD       | 174 | 24.017  | 5.883     |
|                | NO<br>PCOD | 103 | 24.932  | 5.375     |
|                | PCOD       | 174 | 146.226 | 51.876    |
| HEIGHT         | NO<br>PCOD | 103 | 153.177 | 16.979    |
| WEIGHT         | PCOD       | 174 | 59.220  | 17.718    |
|                | NO<br>PCOD | 103 | 54.068  | 10.766    |
| AGE AT         | PCOD       | 174 | 13.063  | 2.006     |
| MENARCH        | NO<br>PCOD | 103 | 13.796  | 1.599     |

#### Table 1: Showing baseline characteristics of the samples included



|   |                  | PCO       | D       | NO PCOD   |         |  |
|---|------------------|-----------|---------|-----------|---------|--|
|   | Categories       | Frequency | Percent | Frequency | Percent |  |
|   | married          | 32        | 18.4    | 20        | 19.4    |  |
| Marital status  | unmarried        | 142       | 81.6    | 83        | 80.6    |  |
|   | a home<br>maker  | 19        | 10.9    | 9         | 8.7     |  |
|   | student          | 116       | 66.7    | 85        | 82.5    |  |
| Occupation  | working<br>womam | 39        | 22.4    | 9         | 8.7     |  |
| consult a doctor<br>regarding your menstural<br>abnormalities | No               |           |         | 97        | 94.2    |  |
|   | Yes              | 174       | 100.0   | 6         | 5.8     |  |
| undergo ultrasound  | No               |           |         | 103       | 100.0   |  |
| scan(USG) for the<br>diagnosis of pcod                        | Yes              | 174       | 100.0   |           |         |  |

Table2:- Baseline

Among individuals with PCOD, 18.4% are married while 81.6% are unmarried, with 10.9% homemakers, 66.7% students, and 22.4% working women. Conversely, in the NO PCOD group, 19.4% are married, 80.6% unmarried, with 8.7% homemakers, 82.5% students, and 8.7% working women. Notably, all PCOD cases have consulted a doctor for menstrual irregularities, while 94.2% in the NO PCOD group have not sought medical advice, and only 5.8% have consulted a doctor. Additionally, all individuals with PCOD have undergone ultrasound scans for diagnosis.

e-ISSN 2583 4304

# **RELIABILITY OF THE TOOL**

In this study, a Cronbach's Alpha value of 0.878 suggests good internal consistency among the items, indicating that they reliably measure the same construct

# **CONSTRUCT VALIDITY**

Exploratory factor analysis Result: The Kaiser-Meyer-Olkin measure of sampling adequacy is 0.890, well exceeding the minimum requirements for conducting Exploratory Analysis. Factor Factor loading represents the correlation coefficient between a variable and a factor, indicating the likelihood of variance explained as "not likely (1)," "somewhat likely (2)," and "very likely (3)." The data were subsequently analysed using SPSS 22 through Principal Component Analysis (PCA) to derive meaningful interpretations.

July 2024; 3(3s):



| e-ISSN                 | e-ISSN 2583 4304 Vol: 3, Issue: 3 July 2 |   |         |
|------------------------|--|---|---------|
|                        |  |   |         |
|                        |  |   | Factor  |
| Question               | S  |   | loading |
| 1) Do yoι              | ı have irregular p                       | eriod   | 0.593   |
| 2) Have y              | ou gained weigh                          | nt in last 3 months?  | .777    |
| 3) Do you              | I feel bloated oft                       | en  | .699    |
| 4) Is the              | fat around your a                        | abdomen more than other are                                   | as .796 |
| 5) Do yoι              | i have frequent f                        | acial acne  | .603    |
| 6) Do you              | I have excessive                         | hairfall leading to baldness?                                 | .544    |
| 7) Do you<br>parts(on  | ı experience exc<br>torso,on breast,     | essive hairgrowth on your bo<br>on back ,on chin and upperlip | dy .733 |
| 8) Do you<br>arms,elbo | i have dark patcl<br>ows or knuckles     | nes around your neck, under                                   | .493    |
| 9) Do you              | I feel hungry ofte                       | en  | .842    |
| 10) Do yo              | ou have constant                         | craving for food  | .788    |
| 11) Do yo              | ou feel tired when                       | n you wake up in the morning                                  | .749    |
| 12) Do yo              | ou experience mo                         | ood swings frequently   | .662    |
| 13) Do yo              | ou have lowerbac                         | ck pain frequently  | .753    |
| 14) Do yo              | ou exercise regul                        | ary?  | .892    |

# **Table 3 Construct Validity**

Most questions have factor loadings above 0.5, indicating a good correlation with the factor, except for Q8, which shows moderate correlation. The order of questions with high correlation to the factor is: Q14, Q9, Q4, Q10, Q2, Q13, Q11, Q7, Q3, Q12, Q5, Q1, Q6, and Q8.

## **CONTENT VALIDITY**

Item level content validity index (96%) meet satisfactory level, and thus the scale of questionnaire has achieved satisfactory level of content validity.



| e-ISSN 2583 4304 |          | Vol: 3, Issue: 3 |        |      |       | July 2024; 3(3s):       |            |      |
|------------------|----------|------------------|--------|------|-------|-------------------------|------------|------|
|                  |          |                  |        |      |       |                         | Experts in | -    |
| Questions        | inv1     | inv2             | inv3   | inv4 | inv5  | inv6                    | agreement  | CVI  |
| 1) Do you        |          |                  |        |      |       |                         |            |      |
| have             |          |                  |        |      |       |                         |            |      |
| irregular        |          |                  |        |      |       |                         |            |      |
| period           | 1        | 1                | 1      | 1    | 1     | 1                       | 1          | 0.17 |
| 2) Have you      |          |                  |        |      |       |                         |            |      |
| gained           |          |                  |        |      |       |                         |            |      |
| weight in        |          |                  |        |      |       |                         |            |      |
| last 3           | 975      | der              | -155.5 |      | 10.00 | 22. V                   | 3          |      |
| months?          | 1        | 1                | 1      | 1    | 1     | 1                       | 6          | 1.00 |
| 3) Do you        |          |                  |        |      |       |                         |            |      |
| feel bloated     |          | 4                |        |      |       |                         |            |      |
| often            | 0        | 1                | 1      | 1    | 1     | 1                       | 5          | 0.83 |
| 4) Is the fat    |          |                  |        |      |       |                         |            |      |
| around your      |          |                  |        |      |       |                         |            |      |
| abdomen          |          |                  |        |      |       |                         |            |      |
| more than        |          |                  | _      |      |       |                         | -          |      |
| other areas      | 0        | 1                | 1      | 1    | 1     | 1                       | 5          | 0.83 |
| 5) Do you        |          |                  |        |      |       |                         |            |      |
| have             |          |                  |        |      |       |                         |            |      |
| frequent         | 1        | 1                | 1      | 1    | 1     | 1                       |            | 1 00 |
| facial ache      | <b>1</b> |                  | 1      |      |       | 1                       | 6          | 1.00 |
| 6) Do you        |          |                  |        |      |       |                         |            |      |
| nave             |          |                  |        |      |       |                         |            |      |
| excessive        |          |                  |        |      |       |                         |            |      |
| hairiali         |          |                  |        |      |       |                         |            |      |
| haldnoss2        | 1        | 1                | 1      | 1    | 1     | 1                       | 6          | 1 00 |
|                  |          | I                | I      | I    | 1     | · · · · · · · · · · · · | 0          | 1.00 |
| 7) Do you        |          |                  |        |      |       |                         |            |      |
| experience       |          |                  |        |      |       |                         |            |      |
| hairgrowth       |          |                  |        |      |       |                         |            |      |
| on vour          | 1        | 1                | 1      | 1    | 1     | 1                       | 6          | 1 00 |
|                  |          |                  |        |      |       |                         | 0          | 1.00 |



| e-ISSN 2583 4304 |      | N N  | Vol: 3, Issue | e: 3 |      | July 2024; 3(3s): |      |      |
|------------------|------|------|---------------|------|------|-------------------|------|------|
|                  |      |      |               |      |      |                   |      |      |
| body             |      |      |               |      |      |                   |      |      |
| parts(on         |      |      |               |      |      |                   |      |      |
| torso,on         |      |      |               |      |      |                   |      |      |
| breast, on       |      |      |               |      |      |                   |      |      |
| back ,on         |      |      |               |      |      |                   |      |      |
| chin and         |      |      |               |      |      |                   |      |      |
| upperlip         |      |      |               |      |      |                   |      |      |
| 8) Do you        |      |      |               |      |      |                   |      |      |
| have dark        |      |      |               |      |      |                   |      |      |
| patches          |      |      |               |      |      |                   |      |      |
| around your      |      |      |               |      |      |                   |      |      |
| neck, under      |      |      |               |      |      |                   |      |      |
| arms,elbows      |      |      |               |      |      |                   |      |      |
| or knuckles      | 1    | 1    | 1             | 1    | 1    | 1                 | 6    | 1.00 |
| 9) Do you        |      |      |               |      |      |                   |      |      |
| feel hungry      |      |      |               |      |      |                   |      |      |
| often            | 1    | 1    | 1             | 1    | 1    | 1                 | 6    | 1.00 |
| 10) Do you       |      |      |               |      |      |                   |      |      |
| have             |      |      |               |      |      |                   |      |      |
| constant         |      |      |               |      |      |                   |      |      |
| craving for      |      | -    | -             |      |      | -                 |      | 1 00 |
| tood             |      |      | 1             | 1    | 1    | ្រា               | 6    | 1.00 |
| () Do you        |      |      |               |      |      |                   |      |      |
| teel tired       |      |      |               |      |      |                   |      |      |
| when you         |      |      |               |      |      |                   |      |      |
| the morning      | 1    | 1    | 1             | 1    | 1    | 1                 | 6    | 1 00 |
| 12) Do you       |      |      | <b>I</b>      | I    | 1    | 1                 | 0    | 1.00 |
| avperience       |      |      |               |      |      |                   |      |      |
| mood             |      |      |               |      |      |                   |      |      |
| swings           |      |      |               |      |      |                   |      |      |
| frequently       | 1    | 1    | 1             | 1    | 1    | 1                 | 6    | 1 00 |
| 13) Do vou       |      |      | · ·           |      |      |                   |      | 1.00 |
| have             |      |      |               |      |      |                   |      |      |
| lowerback        |      |      |               |      |      |                   |      |      |
| pain             |      |      |               |      |      |                   |      |      |
| frequently       | 1    | 1    | 1             | 1    | 1    | 1                 | 6    | 1.00 |
| 14) Do you       |      |      |               |      |      |                   |      |      |
| exercise         |      |      |               |      |      |                   |      |      |
| regulary?        | 1    | 1    | 1             | 1    | 0    | 1                 | 5    | 0.83 |
| Proportion       |      |      |               |      |      |                   |      |      |
| relavance        | 0.86 | 1.00 | 1.00          | 1.00 | 0.93 | 1.00              | 5.79 | 0.96 |
| relavance        | 0.00 | 1.00 | 1.00          | 1.00 | 0.50 | 1.00              | 0.75 | 0.20 |

 Table 4: - content validity



|      | e-ISSN 2583 4304 |          | Vol: 3, | Issue: | 3 July 2024; 3(3s): |                           |
|------|------------------|----------|---------|--------|---------------------|---------------------------|
| Test | t Result Vari    | able(s): | Total   | score  |                     |                           |
|      |                  |          |         |        |                     | Asymptotic 95% Confidence |

|      |                         | Asymptotic        | Asymptotic 95% Confidence<br>Interval |             |  |
|------|-------------------------|-------------------|---------------------------------------|-------------|--|
| Area | Std. Error <sup>a</sup> | Sig. <sup>b</sup> | Lower Bound                           | Upper Bound |  |
| .909 | .018                    | .000              | .874                                  | .944        |  |

 Table: - 5 Area under the curve

The Receiver operating characteristics (ROC) analysis evaluated the "Total score" variable's predictive performance for identifying Polycystic Ovarain disease (PCOD), yielding an Area under the curve (AUC) of 0.909, indicating strong discrimination between PCOD presence and absence. With a standard error of 0.018, this AUC value provides a precise estimate of the variable's predictive ability. The highly significant p-value (p = 0.000) supports the "Total score" variable's statistical significance as a predictor of PCOD. The 95% confidence interval for the AUC is 0.874 to 0.944.







The sensitivity and specificity values, along with the specified cutoff value, provide additional insights into the performance of the diagnostic test for Polycystic Ovarian disease.

The sensitivity and specificity values, along with the specified cut off value, provide additional insight into the performance of the diagnostic test for PCOD.

Specificity: The specificity of 60.2% signifies that the test correctly identifies 60.2% of individuals who do not have PCOD. While this is relatively lower compared to sensitivity, it still suggests that the test has a moderate ability to correctly rule out PCOD in individuals without the condition.

Cutoff Value: The cutoff value of 15.5 is the threshold used to classify individuals into PCOD-positive or PCOD-negative groups based on the Total \_score variable. Individuals with a Total \_score above this cutoff is considered positive for PCOD, and those below are considered negative.

# RESULT

**Reliability of the tool:** In this study, Cronbach's Alpha value of 0.878 suggests good internal consistency among the items, indicating that they reliably measure the same construct.

**Construct validity:** The Kaiser–Meyer– Olkin measure of sampling adequacy was 0.890, which is well above the minimum sampling adequacy requirements for conducting exploratory factor analysis.

**Content validity:** Item level content validity index (96%) meet satisfactory level, and thus the scale of questionnaire has achieved satisfactory level of content validity.

**Sensitivity:** The sensitivity value of 99.4% demonstrates the test's ability to accurately identify individuals with PCOD, reflecting a high true positive rate and effectiveness in detecting genuine case

**Specificity:** With a specificity of 60.2%, the test accurately identifies 60.2% of

individuals without PCOD. Although lower than sensitivity, it still indicates a moderate ability to rule out PCOD in those without the condition.

**Cut off Value:** The cut-off value of 15.5 distinguishes individuals into PCOD-positive or PCOD-negative groups based on the Total score variable. Scores above this threshold indicate PCOD positivity, while scores below signify PCOD negativity.

#### DISCUSSION

Polycystic Ovarian disease (PCOD) is a highly prevalent disorder, representing the single most common endocrine-metabolic disorder in reproductive-aged women. Polycystic ovarian disease is a highly inherited complex polygenic, multifactorial disorder. Women with PCOD are at increased risk for irregular menstrual cvcle. hypertension, subfertility and Obstetric complications like endometrial atypia or carcinoma<sup>. (4)</sup> The prevalence rate of PCOD is high among Indian women. <sup>(5)</sup> Because there was no Awareness or knowledge about PCOD in early stage and people are hesitant to disclose about PCOD.As ultrasound scan and Rotterdam criteria are the only two reliable tool for screening Of PCOD which is out of reach for most of the women in India. due to reasons like Socioeconomic status. As physiotherapist we assist women with PCOD diagnosed with their Weight loss exercise and physical activity regimen <sup>(6)</sup>, our aim was to develop a simple self-made questionnaire based on the major clinical symptoms of PCOD for feasible early Screening of PCOD.

This self-made questionnaire made using Likert scale pattern of 5 demographic questions, 4 Preliminary questions and 14 main questions related to PCOD symptoms in the following order irregular period, weight gain, mood swings, dermatological condition, infertility and so on this selfmade questionnaire was then circulated among the experts in the field of Obstetrics



and gynecology from Dr.B.R. Ambedkar medical College and hospital Bengaluru, India for advice and review of the questionnaire. A few changes suggested by the experts Were made and then with their consent, questionnaire was circulated via Google forms to 277 women between the Age group of 18-45 years according to the inclusion and exclusion criteria, after which the samples were segregated to 174 women who were diagnosed with PCOD and103 women who have not been diagnosed with PCOD further intervention the samples data collected was sent to the biostatistician for analysis of the self-designed questionnaire. **LIMITATION** 

Women are hesitant to disclose their medical conditions related to fertility and menstruation related problems. **RECOMMENDATION** 

- **1.** Further study can be developed on individual domain of the symptoms determining diagnosis of PCOD.
- 2. A comparative study to detect PCOD in early stages using self-made PCOD questionnaire and ultrasound pelvic scan. CONCLUSION

The study concludes that in the self-made questionnaire designed for early diagnosis of PCOD, women can achieve a maximum total score of 42. If the total score surpasses the cut-off value of 15.5, determined using the receiver operating curve, it is considered highly likely that the individual is positive for PCOD. In such cases, further medical interventions are recommended.

#### CONFLICT OF INTEREST Authors declare no conflict of interest REFERENCES

1. H Teed, A Deeks, L Morgan Polycystic ovary syndrome: a complex condition with psychological, Reproductive and metabolic manifestations that impacts on health across the lifespan BMC Med. 2010 Free PMC article, BMC Med. 2010 Jun 30. Doi: 10.1186/1741-7015-8-41.

- G L Jones Benes, T L Clark, R Denham G Holder, T J Haynes, N C Mulgrew, K E Shepherd H Wilkinson Singh, A Balen, H Lashen, W L Ledger. The Polycystic Ovary Syndrome Health-Related Quality of Life questionnaire (PCOSQ): a validation. Hum Reprod. 2004 Feb. Doi: 10.1093/humrep/deh048.
- Kishore K, Jaswal V, Kulkarni V, De D. Practical Guidelines to Develop and Evaluate a Questionnaire. Indian Dermatol Online J. 2021 Mar 2;12(2):266-275. Doi: 10.4103/idoj.IDOJ\_674\_20. PMID: 33959523; PMCID: PMC8088187.
- 4. Ricardo Azziz, Enrico Carmina, Zijiang Chen, Andrea Dunaif, Joop S E Laven, Richard S Legro, Daria Lizneva, Barbara Natterson, Helena J Teede, Bulent O Yildiz polycystic Ovary Syndrome. Orsett Gynecol. 2018 Aug 132(2): 321-336.doi:10.1097/AOG.0000000000268
- 5. Mintu Dewri Bharali, Radhika Rajendran, Jayshree Goswami, Kusum Singal and Vinoth Rajendran Prevalence of polycystic ovarian Syndrome in India: A Systematic Review and Meta-Analysis 2022. 2022 Dec; 14(12): e32351. Published online 2022Dec9.Doi:

10.7759/cureus.32351PMCID:

PMC9826643 PMID: 36628015

- 6. Haidy N, Ashem Gehan A Abdelsamea Physical therapy protocol for obese adolescent girls with polycystic ovarian syndrome: A within-subject design 2019. Annals of clinical andAnalytical Medicine.2019;10(4):496-500.
- Bedrick BS, Eskew AM, Chavarro JE, Jungheim ES. Self-Administered Questionnaire to Screen for Polycystic Ovarian Syndrome. Womens Health Rep (New Rochelle). 2020 Dec 16;1(1):566-573. Doi: 10.1089/whr.2020.0073. PMID: 33786523; PMCID: PMC7785063.
- 8. Boivin MJ, Fatehi F, Phillips-Chan AE, Richardson JR, Summers AN, Foley SA. sExploratory study of a screening measure for polycystic ovarian syndrome, quality of



e-ISSN 2583 4304

Vol: 3, Issue: 3

life assessment, and neuropsychological evaluation. BMC Womens Health. 2020 Jun 23;20(1):132. Doi: 10.1186/s12905-020-00994-8. PMID: 32576264; PMCID: PMC7313190.

- **9.** Ami Vishal Mehta1, Zarna Ronak Shah2, Karan Vishal Mehta3Screening of Polycystic Ovarian Syndrome in Young Females of Gujarat Year: 2021 | Month: January | Volume: 11 | Issue: 1 | Pages: 33-37
- **10.** Kishore K, Jaswal V, Kulkarni V, De D. Practical Guidelines to Develop and Evaluate a Questionnaire. Indian Dermatol

Online J. 2021 Mar 2;12(2):266-275. doi: 10.4103/idoj.IDOJ\_674\_20.PMID:339595 23; PMCID: PMC8088187.

**11.** Wright PJ, Tavakoli AS, Dawson RM. Exploratory factor and confirmatory analyses of the polycystic ovary syndrome health-related quality of life questionnaire (PCOSQ-50). Health Qual Life Outcomes. 2024Feb 3;22(1):15. Doi: 10.1186/s12955-024-02228-z.PMID: 38310238; PMCID: PMC10837866.